ABBOTINDIA25,230.00

Abbott India Ltd.

· Pharma & Health
₹ CrorePeersPFIZERGLAXOIPCALABAJANTPHARMANTHEMMEDANTAGLENMARKBIOCON
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Inventory Days (DIO)399.79518.33563.22
Receivable Days (DSO)19.9121.6519.05
Payable Days (DPO)11.61643.49
Cash Conversion Cycle (days)408.09-61.22
Working Capital Turnover3.071.913.02
Asset Turnover1.131.081.07
Cash Conversion (CFO/Net Income)1.010.720.85
CFO/EBITDA0.830.600.70
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.